Coherent Biopharma received IND study may proceed letter (study permission) from US FDA for its bi-ligand drug conjugate CBP-1018

Coherent Biopharma’s another BESTTM(Bi-Engaging ligand-mediated Selective Targeting)platform pipeline investigational drug, CBP-1018, received study permission (Study May Proceed Letter) from US FDA on July 7, 2021. CBP-1018 is planned for metastatic or recurrent lung cancer, prostate cancer, renal cancer and other solid tumors. Previously, CBP-1018 already received study permission from Chinese NMPA in November 2020, and currently, clinical trial in China is planned to enroll subjects in September 2021. The study permission from FDA for CBP-1018 signifies another important milestone in its clinical development.

By selecting different ligands of tumor cell highly expressed specific receptors, CBP-1018 expands therapeutic areas of Coherent Biopharma’s anticancer drug pipeline. In nonclinical in vitro and in vivo studies, CBP-1018 is highly receptor specific and demonstrates high tissue penetration, potent antitumor activities, and wide safety margins.